|Bid||1.1200 x 3000|
|Ask||1.1300 x 21500|
|Day's Range||1.1200 - 1.1583|
|52 Week Range||1.1200 - 5.3300|
|Beta (5Y Monthly)||1.37|
|PE Ratio (TTM)||3.06|
|Earnings Date||Oct 29, 2020|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||2.70|
Lexicon (LXRX) delivered earnings and revenue surprises of 57.78% and -94.43%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?
Shares of Lexicon Pharmaceuticals (NASDAQ:LXRX) rose 5.7% in pre-market trading after the company reported Q3 results.Quarterly Results Earnings per share decreased 330.00% year over year to ($0.43), which missed the estimate of $0.26.Revenue of $6,634,000 decreased by 97.75% from the same period last year, which missed the estimate of $16,870,000.Outlook Earnings guidance hasn't been issued by the company for now.View more earnings on LXRXRevenue guidance hasn't been issued by the company for now.Recent Stock Performance 52-week high: $5.3352-week low: $1.22Price action over last quarter: down 33.51%Company Description Lexicon Pharmaceuticals Inc is a biopharmaceutical company developing medicines that transform patients' lives. The company commercializes and develops drugs and drug candidates. Its drugs candidates include XERMELO (telotristat ethyl), an orally-delivered small molecule drug, in the United States for the treatment of carcinoid syndrome diarrhea in combination with somatostatin analog, or SSA, therapy in adults inadequately controlled by SSA therapy; Zynquista (sotagliflozin), an orally-delivered small molecule drug candidate, as a treatment for type 1 diabetes; sotagliflozin as a treatment for type 2 diabetes, heart failure and chronic kidney disease; and LX9211, an orally-delivered small molecule drug candidate, as a treatment for neuropathic pain.See more from Benzinga * Click here for options trades from Benzinga * 12 Healthcare Stocks Moving In Wednesday's After-Market Session * Stocks That Hit 52-Week Lows On Wednesday(C) 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
NEW YORK, NY / ACCESSWIRE / October 29, 2020 / Lexicon Pharmaceuticals, Inc.